微RNA-122在原发性肝癌围手术期的表达和预后价值的研究进展

doi:10.20047/j.issn1673-7210.2023.28.13

Abstract
Figure/Table
References (33)
Related Citation (15)

Download: PDF (492 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Primary liver cancer is one of the most common malignant tumors in clinic. It has the characteristics of poor prognosis and high mortality. With the deepening of research, many new techniques in clinic have been developed in the diagnosis and treatment of liver diseases. Among them, microRNA (miRNA) have become a new target for the treatment of liver diseases due to their high conservation, timing, stability, and tissue specificity. MiRNA-122 is a specific miRNA in liver tissue, which can inhibit the progression of primary liver cancer by regulating the expression of corresponding target molecules in liver cells. In recent years, studies on the value of miRNA-122 in primary liver cancer surgery have been carried out one after another, and they have shown certain advantages. Monitoring miRNA-122 during perioperative period of liver surgery is of great value for disease assessment and prognosis. This article reviews the expression and prognostic value of miRNA-122 in perioperative primary liver cancer.

Key words： MicroRNA-122 Primary liver cancer Perioperative period Expression Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jialing1 LI Yuebing2

Cite this article:

ZHANG Jialing1 LI Yuebing2. Research progress on the expression and prognostic value of microRNA-122 in perioperative period of primary liver cancer[J]. 中国医药导报, 2023, 20(28): 62-65.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.28.13 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I28/62

[1] 赫捷，陈万青，沈洪兵，等.中国人群肝癌筛查指南（2022，北京）[J].中国肿瘤，2022，31（8）：587-631.
[2] 贾昊宇，杨长青.肝脏疾病的现代治疗方法[J].肝脏，2022，27（9）：950-953.
[3] Badami E，Busà R，Douradinha B，et al. Hepatocellular carcinoma，hepatitis C virus infection and miRNA involvement：Perspectives for new therapeutic approaches [J]. World J Gastroenterol，2022，28（22）：2417-2428.
[4] Manzoor S，Malik IR，Jahan S，et al. Serum MicroRNAs as Predictors for HCV Progression and Response to Treatment in Pakistani Patients [J]. Genes（Basel），2023，14（2）：441.
[5] Kunden RD，Khan JQ，Ghezelbash S，et al. The Role of the Liver-Specific microRNA，miRNA-122 in the HCV Replication Cycle [J]. Int J Mol Sci，2020，21（16）：5677.
[6] Liu Y，Song JW，Lin JY，et al. Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases [J]. Cardiovasc Toxicol，2020，20（5）：463-473.
[7] Turshudzhyan A，Wu GY. Persistently Rising Alpha-fetoprotein in the Diagnosis of Hepatocellular Carcinoma：A Review [J]. J Clin Transl Hepatol，2022，10（1）：159-163.
[8] Amr KS，Elmawgoud Atia HA，Elazeem Elbnhawy RA，et al. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma [J]. Genes Dis，2017，4（4）：215-221.
[9] Hamad RS，Al Abdulsalam NK，Elrefaiy MA，et al. Interplay between TGF-b1 and miRNA-122 biomarkers in hepatocellular carcinoma progression in patients with chronic hepatitis C [J]. Trop Biomed，2022，39（4）：559-568.
[10] Zhou J，Shi K，Huang W，et al. LncRNA RPPH1 acts as a molecular sponge for miR-122 to regulate Wnt1/β-catenin signaling in hepatocellular carcinoma [J]. Int J Med Sci，2023，20（1）：23-34.
[11] 吕炎，王艳华，苏利佳，等.miRNA-122在肿瘤发生发展中的研究进展[J].癌症进展，2021，19（18）：1847-1851.
[12] Taniguchi K， Uchiyama K， Akao Y. PTBP1-targeting microRNAs regulate cancer-specific energy metabolism through the modulation of PKM1/M2 splicing [J]. Cancer Sci，2021， 112（1）：41-50.
[13] Zhou X，Fang S，Wang M，et al. Diagnostic value of circulating miRNA-122 for hepatitis B virus and/or hepatitis C virus-associated chronic viral hepatitis [J]. Biosci Rep，2019， 39（9）：BSR20190900.
[14] Shehab-Eldeen S，Nada A，Abou-Elela D，et al. Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma（HCC）[J]. Asian Pac J Cancer Prev，2019，20（8）：2515- 2522.
[15] Atic AI，Thiele M，Munk A，et al. Circulating miRNAs associated with nonalcoholic fatty liver disease [J]. Am J Physiol Cell Physiol，2023，324（2）：C588-C602.
[16] 王兆林，王盖昊，杨婉，等.miRNA-122异常表达在肝细胞癌发生中的研究进展[J].肝脏，2015，20（2）：157-160.
[17] Wu J，Wu Y，Luo Y，et al. Circulating miRNA-199a and miRNA-122 Levels as Potential Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma [J]. Ann Clin Lab Sci，2020，50（2）：219-227.
[18] Christou CD，Tsoulfas G. The Role of microRNA in Hepatic Ischemia/Reperfusion Injury [J]. Microrna，2020，9（4）：248- 254.
[19] 李珺媛，姚明江，范晓迪.缺氧诱导因子-1α在缺血性脑卒中后神经修复中的作用及中医药干预研究进展[J].中华中医药杂志，2022，37（8）：4579-4583.
[20] Ju C，Wang M，Tak E，et al. Hypoxia-inducible factor-1α-dependent induction of miR122 enhances hepatic ischemia tolerance [J]. J Clin Invest，2021，131（7）：e140300.
[21] Zhang K，Xu X，Hu L. Sevoflurane attenuates hepatic ischemia reperfusion injury by the miR-122/Nrf2 pathway [J]. Ann Transl Med，2022，10（6）：350.
[22] Duan YF，An Y，Zhu F，et al. Remote ischemic preconditioning protects liver ischemia-reperfusion injury by regulating eNOS-NO pathway and liver microRNA expressions in fatty liver rats [J]. Hepatobiliary Pancreat Dis Int，2017， 16（4）：387-394.
[23] Yang G，Zhang M，Zhao Y，et al. HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122- adam17 pathway [J]. PLoS One，2020，15（3）：e0230450.
[24] Wang X，He Y，Mackowiak B，et al. MicroRNAs as regulators，biomarkers and therapeutic targets in liver diseases [J]. Gut，2021，70（4）：784-795.
[25] Wu J，Zhou X，Li P，et al. Ultrasensitive and Simultaneous SERS Detection of Multiplex MicroRNA Using Fractal Gold Nanotags for Early Diagnosis and Prognosis of Hepatocellular Carcinoma [J]. Anal Chem，2021，93（25）：8799-8809.
[26] Starlinger P，Hackl H，Pereyra D，et al. Predicting Postoperative Liver Dysfunction Based on Blood-Derived MicroRNA Signatures [J]. Hepatology，2019，69（6）：2636- 2651.
[27] Wang S，Yang Y，Sun L，et al. Exosomal MicroRNAs as Liquid Biopsy Biomarkers in Hepatocellular Carcinoma [J]. Onco Targets Ther，2020，13：2021-2030.
[28] Bulfoni M，Pravisani R，Dalla E，et al. miRNA expression profiles in liver grafts of HCV and HIV/HCV-infected recipients，6 months after liver transplantation [J]. J Med Virol，2021，93（8）：4992-5000.
[29] Yahya SMM，Fathy SA，El-Khayat ZA，et al. Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma [J]. Indian J Clin Biochem，2018， 33（1）：21-30.
[30] Chowdhury SM，Lee T，Bachawal SV，et al. Longitudinal assessment of ultrasound-guided complementary microRNA therapy of hepatocellular carcinoma [J]. J Control Release，2018，281：19-28.
[31] Wang H，Ellipilli S，Lee WJ，et al. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance [J]. J Control Release，2021，330：173-184.
[32] Ning Q，Liu YF，Ye PJ，et al. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma[J]. ACS Appl Mater Interfaces，2019，11（11）：10578-10588.
[33] Elfert AY，Salem A，Abdelhamid AM，et al. Implication of miR-122，miR-483，and miR-335 Expression Levels as Potential Signatures in HCV-Related Hepatocellular Carcinoma（HCC）in Egyptian Patients [J]. Front Mol Biosci，2022，9：864839.